Statute Details
- Title: Health Products (Advertisement of Specified Health Products) Regulations 2016
- Act Code: HPA2007-S333-2016
- Legislative Type: Subsidiary legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D)
- Enacting Authority: Health Sciences Authority (HSA), with Minister for Health’s approval
- Commencement: 1 November 2016 (amended version current as at 27 Mar 2026)
- Key Amendments Noted: Amended by S 109/2021 with effect from 1 March 2021
- Primary Purpose: Regulates how “specified health products” may be advertised in Singapore
- Key Provisions (from extract): Regulations 2–15 (definitions; general requirements; exclusions; substantiation; disease/condition restrictions; prescription/pharmacy-only rules; unregistered products; sales promotions; professional/scientific info; reference/trade ads; informational statements; sales promotions involving registered products; power to require copies)
- Schedules: First Schedule (relevant to “CTGT product” and “therapeutic product” categorisation); Second Schedule (specified health products); Third Schedule (specified diseases or conditions)
What Is This Legislation About?
The Health Products (Advertisement of Specified Health Products) Regulations 2016 (“Advertisement Regulations”) are Singapore’s detailed rules governing advertising of health products that fall within the statutory definition of “specified health products”. The overarching policy is consumer protection: advertisements must not mislead the public, must not encourage unsafe self-treatment, and must not create unrealistic expectations about health outcomes.
In plain terms, the Regulations set boundaries on what advertisers can say and show when promoting health products. They also impose additional restrictions depending on the product’s regulatory classification—particularly whether it is a prescription-only medicine, a pharmacy-only medicine, or otherwise a “specified health product” under the Health Products Act framework.
Practically, the Regulations operate alongside the Health Products Act (Cap. 122D). The Act provides the licensing and regulatory architecture for health products; the Advertisement Regulations focus specifically on the content and conduct of advertising. They are therefore central for compliance by manufacturers, importers, wholesalers, retailers, and any third parties that publish or distribute promotional materials.
What Are the Key Provisions?
1. Definitions and scope (Regulation 2)
The Regulations define key terms that determine who is regulated and what conduct is captured. Notably, “specified health product” is defined by reference to the Second Schedule. The Regulations also define “publish” broadly (including distributing, showing, displaying, exhibiting, issuing, disseminating or broadcasting by any form of communication). This breadth matters for modern marketing channels such as websites, social media posts, influencer content, and targeted online advertisements.
Other important definitions include “non-public sector person” (a person other than a public authority established by a public Act for a public purpose, or a person authorised by the Minister), “licensee” (manufacturer/importer/wholesaler licence holders for the product), and “sales promotion” (a wide concept including door-to-door sales, exhibitions, competitions, and other activities meant to introduce or raise awareness for the purpose of promoting sale or use).
2. Baseline compliance framework (Regulation 3)
Regulation 3 ties advertising compliance to section 21(1) of the Health Products Act. It provides that an advertisement must, subject to modifications for certain categories of advertising (Regulations 11–14), do two things: (a) comply with Regulations 4, 5 and 6; and (b) be undertaken in accordance with additional requirements depending on product type. For “any specified health product”, the advertisement must comply with Regulations 7, 9 and 10; for a “therapeutic product only”, it must comply with Regulation 8.
This structure is important for practitioners because it creates a layered compliance checklist: first, the general prohibitions and substantiation rules; second, category-specific restrictions (e.g., prescription-only vs pharmacy-only medicines).
3. Matters excluded from advertising (Regulation 4)
Regulation 4 is a core consumer-protection provision. It prohibits advertisements from containing or doing various things, including content that is likely to lead consumers to self-diagnose or inappropriately treat serious diseases; that suggests pharmacist or qualified practitioner advice is unnecessary; or that implies medical consultation or surgery is not necessary if the product is used.
The provision also targets misleading or fear-inducing marketing. Examples include advertisements that mislead about quality or efficacy; compare or contrast the product with other named products or brands; exploit consumers’ lack of knowledge; use language or images that cause fear, alarm or distress; or claim the product is “infallible, unfailing, magical or miraculous”.
Regulation 4 further prohibits certain commercial inducements and endorsement misrepresentations. Advertisements must not offer refunds or guarantee refunds of purchase price; must not falsely claim Government or public authority endorsement; must not be directed principally at persons below age 14; and must not contain any endorsement or recommendation by healthcare professionals or by celebrities/social/professional figures likely to encourage use.
4. Substantiation of uniqueness and prominence claims (Regulation 5)
Where an advertisement includes statements asserting uniqueness or prominence—such as awards, certifications, or features differentiating the product—those claims must be substantiated by facts or evidence. This is a “substantiation” rule: it does not necessarily forbid uniqueness claims, but it requires that the advertiser can support them with verifiable evidence.
5. Restrictions on promoting for specified diseases/conditions and prescription-only medicines (Regulations 6 and 7)
Although the extract provided truncates the text of Regulations 6 and 7, the headings indicate two major compliance themes. Regulation 6 restricts promoting specified health products for “specified diseases or conditions” (referenced by the Third Schedule). Regulation 7 prohibits advertisement of prescription-only medicines.
For legal and compliance work, the practical consequence is that advertisers must check (i) whether the product is within the relevant category; and (ii) whether the advertisement’s therapeutic messaging relates to diseases/conditions that trigger the “specified” restrictions. If it does, the advertisement may be prohibited or must meet additional conditions.
6. Pharmacy-only medicines: prominence requirement (Regulation 8)
Regulation 8 requires that advertisements of a “pharmacy-only medicine” by a non-public sector person must prominently display specified information. While the extract does not show the exact wording of the display requirement, the legal effect is clear: the advertisement must include a prominent warning or instruction (typically relating to the need to consult a pharmacist or to obtain the product through appropriate channels). This is designed to prevent consumers from treating pharmacy-only medicines as freely self-selectable products.
7. Unregistered specified health products (Regulation 9)
Regulation 9 sets requirements for advertisements of specified health products that are not registered under the Act. This typically means that advertisers cannot simply market unregistered products as if they were approved; they must meet conditions that ensure the public is not misled about regulatory status.
8. Sales promotions (Regulation 10) and related advertising formats (Regulations 11–14)
Sales promotions are treated as a distinct risk area because they often involve aggressive marketing techniques, incentives, and heightened consumer attention. Regulation 10 prohibits certain conduct in sales promotions involving specified health products (the extract truncates the operative text, but the heading and structure indicate restrictions on how promotions may be conducted).
Regulations 11–14 address other advertising categories. For example, Regulation 11 concerns professional or scientific information advertising, which may be treated differently from consumer-facing promotional claims. Regulations 12 and 13 address reference/trade advertisements and informational statements, respectively—likely allowing certain factual or non-promotional communications, provided they do not cross into prohibited promotional messaging. Regulation 14 specifically addresses sales promotions involving registered specified health products, suggesting that registration status affects what is permissible.
9. Regulatory oversight: power to require copies (Regulation 15)
Regulation 15 gives the Authority (HSA) power to require, by written notice, that any person who advertises (or causes advertisements to be advertised) provide copies of the advertisements. This is a key enforcement tool. It enables the Authority to investigate compliance, verify substantiation, and assess whether the advertisement content meets the Regulations’ requirements.
How Is This Legislation Structured?
The Regulations are structured as a set of numbered regulations with three schedules. The main body contains:
Regulations 1–2: citation/commencement and definitions.
Regulations 3–5: general requirements for advertisements, exclusions, and substantiation of uniqueness/prominence claims.
Regulations 6–10: category-specific restrictions, including disease/condition limitations, prescription-only prohibitions, pharmacy-only prominence requirements, rules for unregistered products, and restrictions on sales promotions.
Regulations 11–14: special treatment for professional/scientific information, reference/trade advertisements, informational statements, and sales promotions involving registered products.
Regulation 15: HSA’s power to require copies of advertisements.
The First Schedule is used for categorisation concepts such as “CTGT product” and “therapeutic product” (as referenced in Regulation 2). The Second Schedule lists “specified health products”. The Third Schedule lists “specified diseases or conditions” relevant to Regulation 6.
Who Does This Legislation Apply To?
The Regulations apply to “advertisements” of “specified health products” and therefore capture a wide range of actors involved in marketing and publication. The definition of “publish” is broad, so the rules can apply not only to the advertiser (e.g., a manufacturer or distributor) but also to anyone who disseminates or displays promotional content.
Special rules apply depending on whether the advertiser is a “non-public sector person”. For example, Regulation 6–10 and related provisions distinguish between public sector and non-public sector advertising. In practice, compliance teams should assume that commercial entities—manufacturers, importers, wholesalers, retailers, and marketing agencies—are within scope, particularly where they are promoting sale or use of specified health products.
Why Is This Legislation Important?
For practitioners, these Regulations are important because they translate the Health Products Act’s consumer-protection objectives into concrete, enforceable advertising rules. The prohibitions in Regulation 4 are especially significant: they cover not only false or misleading claims, but also marketing techniques that can lead to unsafe self-treatment, fear-based messaging, and improper endorsement or celebrity promotion.
The substantiation requirement in Regulation 5 is also a frequent compliance flashpoint. Many health product advertisements rely on “unique” claims, awards, certifications, or comparative superiority language. The Regulations require evidence for such claims, which means legal review should verify that substantiation exists and is capable of supporting the exact wording used in the advertisement.
Finally, the Authority’s power under Regulation 15 to require copies of advertisements underscores that compliance is not merely prospective. Advertisers should maintain records of approvals, substantiation documents, and final advertisement versions. In investigations, the ability to produce copies and evidence quickly can be decisive.
Related Legislation
- Health Products Act (Cap. 122D)
- Medicines Act
- Medical Registration Act
- Dental Registration Act
- Midwives Act
Source Documents
This article provides an overview of the Health Products (Advertisement of Specified Health Products) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.